University of Colorado Health

Quarterly bond compliance packet

For the quarter ending March 31, 2023



uchealth

Unaudited Results University of Colorado Health Comparative Summary Statements of Income & Changes in Fund Balances

uchealth

For the Quarter Ended March 31, 2023 (in Thousands)

		Obligated	System Consolidated		
	Gr	oup Total ²			
Operating Revenue					
Net Patient Revenue 1	\$	1,683,331	\$	1,704,277	
Grant Revenue		2,479		2,759	
Other Operating Revenue		16,450		18,159	
Total Net Operating Revenue	\$	1,702,260	\$	1,725,195	
Operating Expenses:					
Wages, Contract labor, & benefits	\$	781,561	\$	790,257	
Supplies		418,750		425,569	
Purchased Services & Other Expenses		353,103		365,018	
Depreciation and Amortization		80,636		82,581	
Total Operating Expense	\$	1,634,051	\$	1,663,425	
Operating Income (Loss)	\$	68,209	\$	61,770	
Nonoperating revenue & expenses					
Interest Expense	\$	(6,466)	\$	(6,835)	
Investment Income		246,647		250,011	
Other Non-Operating Revenue		(2,643)		(8,140)	
Gain (Loss) Disposal Cap		30		30_	
Total Nonoperating Income	\$	237,568	\$	235,065	
Income Before Contributions	\$	305,777	\$	296,834	
Non-Recurring	\$	-	\$	-	
Restricted contributions		(38,738)		1,144	
Distribution of Net Assets		(267)		(267)	
Increase (Decrease) in Net Assets	\$	266,772	\$	297,711	

Unaudited Results University of Colorado Health Comparative Summary Statements of Income & Changes in Fund Balances

uchealth

For the Fiscal Year-to-Date March 31, 2023 (in Thousands)

	(Obligated	System		
	Gr	oup Total ²	Consolidated		
Operating Revenue					
Net Patient Revenue 1	\$	4,961,048	\$	5,021,933	
Grant Revenue		4,556		5,465	
Other Operating Revenue		56,410		67,081	
Total Net Operating Revenue	\$	5,022,013	\$	5,094,479	
Operating Expenses:					
Wages, Contract labor, & benefits	\$	2,306,966	\$	2,334,303	
Supplies		1,237,018		1,256,918	
Purchased Services & Other Expenses		1,017,868		1,055,677	
Depreciation and Amortization		244,104		249,652	
Total Operating Expense	\$	4,805,955	\$	4,896,550	
Operating Income (Loss)	\$	216,058	\$	197,929	
Nonoperating revenue & expenses					
Interest Expense	\$	(22,870)	\$	(24,040)	
Investment Income		349,701		353,907	
Other Non-Operating Revenue		(20,158)		(26,028)	
Gain (Loss) Disposal Cap		64		64	
Total Nonoperating Income	\$	306,737	\$	303,904	
Income Before Contributions	\$	522,795	\$	501,833	
Non-Recurring	\$	-	\$	-	
Restricted contributions		(38,636)		2,354	
Distribution of Net Assets		(1,012)		(1,012)	
Increase (Decrease) in Net Assets	\$	483,147	\$	503,175	



		March 31, 2023			
		Obligated System			
		Group ¹		Consolidated	
Current assets					
Cash and cash equivalents	\$	246,828	\$	259,550	
Patient accounts receivable, less allowances for uncollectible accounts		700,113		707,096	
Other receivables		138,154		82,176	
Inventories		126,414		137,821	
Prepaid expenses		120,999		122,116	
Investments designated for liquidity support		219,755		219,755	
Total current assets	\$	1,552,262	\$	1,528,516	
Non-current assets					
Restricted investments, bonds	\$	0	\$	0	
Restricted investments, other		840		840	
Restricted investments and donor pledges		13,910		57,746	
Capital assets, net of accumulated depreciation and amortization		3,635,554		3,657,482	
Long-term investments		2,136,112		2,179,962	
Assets designated for long-term purposes		2,943,246		2,943,246	
Other investments		103,886		108,863	
Other assets		93,980		94,120	
Deferred outflows of resources		120,631		121,289	
Total non-current assets	\$	9,048,159	\$	9,163,548	
Total assets	\$	10,600,421	\$	10,692,063	
Current liabilities					
Current portion of long-term debt	\$	69,954	Φ	70,403	
Accounts payable and accrued expenses		00,00.	\$		
Accounts payable - construction		696,086	Ф	706,721	
	·	,	Ф	706,721 60,413	
Accrued compensated absences		696,086	Ф	•	
Accrued compensated absences Accrued interest payable	·	696,086 60,413	Φ	60,413	
		696,086 60,413 126,542	Φ	60,413 127,827	
Accrued interest payable		696,086 60,413 126,542	Φ	60,413 127,827	
Accrued interest payable Fair value of derivative instruments		696,086 60,413 126,542 9,248	Φ	60,413 127,827 9,248	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements	\$	696,086 60,413 126,542 9,248 - 212,782	\$	60,413 127,827 9,248 - 212,782	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements	\$	696,086 60,413 126,542 9,248 - 212,782 219,755		60,413 127,827 9,248 - 212,782 219,755	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements Total current liabilities Long-term liabilities	<u>.</u>	696,086 60,413 126,542 9,248 - 212,782 219,755 1,394,780	\$	60,413 127,827 9,248 - 212,782 219,755 1,407,149	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements Total current liabilities	\$	696,086 60,413 126,542 9,248 - 212,782 219,755		60,413 127,827 9,248 - 212,782 219,755	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements Total current liabilities Long-term liabilities Long-term debt, less current portion	<u>.</u>	696,086 60,413 126,542 9,248 - 212,782 219,755 1,394,780	\$	60,413 127,827 9,248 - 212,782 219,755 1,407,149	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements Total current liabilities Long-term liabilities Long-term debt, less current portion Fair value of derivative instruments, less current portion	<u>.</u>	696,086 60,413 126,542 9,248 - 212,782 219,755 1,394,780 1,257,069 0	\$	60,413 127,827 9,248 - 212,782 219,755 1,407,149 1,260,659 0	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements Total current liabilities Long-term liabilities Long-term debt, less current portion Fair value of derivative instruments, less current portion Other long-term liabilities	<u>.</u>	696,086 60,413 126,542 9,248 - 212,782 219,755 1,394,780 1,257,069 0 250,354	\$	60,413 127,827 9,248 - 212,782 219,755 1,407,149 1,260,659 0 250,435	
Accrued interest payable Fair value of derivative instruments Estimated third-party settlements Long-term debt subject to short-term remarketing arrangements Total current liabilities Long-term liabilities Long-term debt, less current portion Fair value of derivative instruments, less current portion Other long-term liabilities Deferred inflows of resources	\$	696,086 60,413 126,542 9,248 - 212,782 219,755 1,394,780 1,257,069 0 250,354 72,001	\$	60,413 127,827 9,248 - 212,782 219,755 1,407,149 1,260,659 0 250,435 72,001	



	Quarter 3		Fiscal Year-to-Date		
		System		System	
		nsolidated	Co	onsolidated	
Cash flows from operating activities					
Cash received from patients and third-party payors	\$	1,680,155	\$	5,016,678	
Cash payments to suppliers for goods and services	•	(833,190)	•	(2,367,635)	
Cash payments to employees/other on behalf of employees		(738,831)		(2,268,847)	
Other cash payments		(9,213)		(28,159)	
Other cash received		14,279		52,442	
Net cash provided by operating activities		113,200		404,479	
Cash flows from capital and related financing activities					
Proceeds from long-term debt		-		-	
Principal payments under capital lease obligations		(8,940)		(28,756)	
Principal repayments of long-term debt		-		(8,115)	
Payments of interest and issuance costs on long-term debt		(3,046)		(25,596)	
Capital expenditures		(148,318)		(413,816)	
Receipt of contributions		1,175		2,414	
(Distributions to) contributions from minority interest in component unit		(583)		(1,327)	
Proceeds from sale of capital assets		39		123	
Net cash used in capital and related financing activities		(159,673)		(475,073)	
Cash flows from noncapital financing activities					
Receipt of grant revenue Net cash provided by noncapital financing activities		-		-	
Cash flows from Investing activities					
Investment income		61,206		137,688	
Distributions received from joint ventures		2,658		11,783	
Loans repaid by third parties		209		953	
Proceeds from sale and maturities of investments		806,871		1,990,862	
Purchases of investments		(790,937)		(2,096,389)	
Net cash used in investing activities		80,007		44,897	
Net increase (decrease) in cash and cash equivalents		33,534		(25,697)	
Cash and cash equivalents at beginning of period		313,179		313,179	
Cash and cash equivalents at end of period	\$	346,713	\$	287,482	
Reconciliation of operating income to net cash provided by operating activities:					
Operating income	\$	61,770	\$	197,929	
Adjustments to reconcile operating income to net cash provided by operating activities	<u> </u>	0.,0	<u> </u>	.0.,020	
Depreciation and amortization		82,581		249,652	
Provision for bad debts		65,143		246,789	
Decrease (increase) in patient accounts receivable		(86,550)		(278,069)	
Increase (decrease) in estimated third-party settlements		(2,715)		26,025	
Decrease (increase) in other receivables and receivables from related parties		(2,438)		(1,452)	
Decrease (increase) in inventories		1,277		2,212	
Change in net pension assets/liabilities		9,043		22,754	
Decrease (increase) in prepaid expenses		(6,974)		(10,826)	
Decrease (increase) in other assets		3,389		5,138	
Increase (decrease) in accounts payable and accrued expenses		3,210		(11,787)	
Increase (decrease) in accrued compensated absences and other		108		1,982	
Equity income from joint ventures		(1,285)		(9,002)	
Adjustments to other cash receipts/payments		(13,359)		(36,866)	
Total adjustments		51,430		206,550	
Net cash provided by operating activities	\$	113,200	\$	404,479	
Non-cash transactions:			_	_	
Donated pharmaceuticals	\$	1,558	\$	4,422	
Construction in progress accrued	\$	60,413	\$	60,413	
Non-cash capital purchase	\$	-	\$	-	
Unrealized gain (loss)	\$	241,355	\$	255,683	
Refunding of debt	\$	-	\$	245,176	
Unrealized gain (loss) on derivative instruments	\$	(9,357)	\$	16,749	
Leases executed/cancelled	\$	12,035	\$	14,995	

Unaudited Results University of Colorado Health Footnotes to Quarterly Bond Compliance Packet March 31, 2023



- ¹ In accordance with GASB 34, bad debt expense is classified as a reduction of net patient service revenue.
- Obligated group members include: University of Colorado Health, University of Colorado Hospital Authority, Poudre Valley Health Care, Inc., Medical Center of the Rockies, Longs Peak Hospital, Yampa Valley Medical Center, and Poudre Valley Medical Group LLC, UCHealth Broomfield Hospital, UCHealth Grandview Hospital, UCHealth Pikes Peak Regional Hospital, UCHealth Highlands Ranch Hospital, UCHealth Greeley Hospital, UCHealth Community Services

In 2017, the GASB issued Statement No. 87, Leases, which improves the accounting and financial reporting for leases by governments for the financial statement users. GASB Statement No. 87 increases the usefulness of governments' financial statements by requiring recognition of certain lease assets and liabilities for leases that previously were classified as operating leases and recognized as inflows of resources or outflows of resources based on the payment provisions of the contract. It establishes a single model for lease accounting based on the foundational principle that leases are financings of the right to use an underlying asset. Under GASB Statement No. 87, a lessee is required to recognize a lease liability and an intangible right-to-use lease asset, and a lessor is required to recognize a lease receivable and a deferred inflow of resources, thereby enhancing the relevance and consistency of information about governments' leasing activities. UCHealth adopted this statement effective July 1, 2020. The adoption impacted the combined balance sheet by adding right of use assets of \$333,016,287 and corresponding lease liability of \$213,248,065 as of the date of adoption. This adoption impacts the Statement of Income & Changes in Fund Balances, Balance Sheet, Statement of Cash Flows, and Financial Covenant Calculations.

